Wednesday, January 03, 2024 9:24:41 AM
https://finance.yahoo.com/news/esperion-daiichi-sankyo-europe-announce-120000052.html
– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet –
– Amendment also includes transfer of certain manufacturing and supply rights to DSE and expansion of collaboration in Europe and other territories –
ANN ARBOR, Mich. & MUNICH, January 03, 2024--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), announced today a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.
DSE has agreed to pay Esperion $100 million in mid-January ahead of an anticipated Type II(a) variation approval by the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet. DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application. The legal action pending in the United States District Court for the Southern District of New York will be dismissed.
The parties also agreed, as part of the resolution:
for Esperion to transition to DSE manufacturing and supply responsibilities in Europe and other territories, resulting in significant cost savings and efficiencies for both companies.
to expand their collaboration in Europe and other territories, to include the potential development and commercialization of a triple formulation product comprising bempedoic acid, ezetimibe and a statin, which could represent significant long-term value for the collaboration.
for DSE to now lead all regulatory communications with the EMA regarding the pending applications.
"We are pleased that this settlement creates value for Esperion today through cash payments and includes additional terms that will continue creating value for both companies going forward. Importantly, today’s settlement allows Esperion and DSE to focus on the business at hand – delivering life-saving drug therapies to millions with high cholesterol," said Sheldon Koenig, Esperion’s President and CEO. "Together, we are committed to making bempedoic acid a blockbuster franchise worldwide, based on the differentiating profiles of our products."
"This is a positive resolution for patients. We look forward to continuing to apply our combined strengths around the world to bring innovative pharmaceutical products to patients with cardiovascular disease, the greatest cause of death and disability globally," said Oliver Appelhans, Head of the Specialty Business Unit of Daiichi Sankyo Europe.
Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction. The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.
Recent ESPR News
- Esperion to Report First Quarter 2024 Financial Results on May 7 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity • GlobeNewswire Inc. • 04/07/2024 06:45:00 PM
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 • GlobeNewswire Inc. • 03/25/2024 08:00:00 PM
- U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use • Business Wire • 03/22/2024 10:26:00 PM
- U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use • GlobeNewswire Inc. • 03/22/2024 07:10:20 PM
- CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events • GlobeNewswire Inc. • 03/22/2024 03:04:39 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 02:19:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:23:29 PM
- Esperion Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/27/2024 11:00:00 AM
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/16/2024 09:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:50:20 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:42:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:11:31 AM
- Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 • GlobeNewswire Inc. • 02/13/2024 01:00:00 PM
- RFK, Esperion Therapeutics Announce 2024 Promotional Schedule • GlobeNewswire Inc. • 02/01/2024 07:00:00 PM
- Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 01/23/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:10:03 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/22/2024 11:04:57 AM
- Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock • GlobeNewswire Inc. • 01/19/2024 02:15:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:03:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/18/2024 09:01:29 PM
- Esperion Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 01/18/2024 09:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM